SavedAdd your journal

Journals / Türkderm Türk deri hastalıkları ve frengi arşivi / 2020 / Cilt: 54 - Sayı: 2

Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology

COVID-19 pandemisi süresince ürtiker ve atopik dermatitte sistemik tedavilerin kullanımına ilişkin öneriler: Türk Dermatoloji Derneği Dermatoallerji Çalışma Grubu Bildirisi

Murat BORLU
Ekin ŞAVK
Emek KOCATÜRK
Ülker GÜL
Andaç SALMAN
Sibel ALPER
Nilgün ATAKAN
Emel BÜLBÜL BAŞKAN
Filiz CANBOLAT
Teoman ERDEM
Yasemin ERDEM
Selda Pelin KARTAL
Rafet KOCA
Özlem SU KÜÇÜK
Zerrin ÖĞRETMEN
Esen ÖZKAYA
Hayriye SARICAOĞLU
Oktay TAŞKAPAN
Serap UTAŞ
Pages
71–75
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

BORLU, M., ŞAVK, E., KOCATÜRK, E., GÜL, Ü., SALMAN, A., ALPER, S., ATAKAN, N., BAŞKAN, E. B., CANBOLAT, F., ERDEM, T., ERDEM, Y., KARTAL, S. P., KOCA, R., KÜÇÜK, Ö. S., ÖĞRETMEN, Z., ÖZKAYA, E., SARICAOĞLU, H., TAŞKAPAN, O., UTAŞ, S. (2022). Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology. Türkderm Türk deri hastalıkları ve frengi arşivi, Cilt: 54 - Sayı: 2, 71–75. https://ajindex.com/articles/654737

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. T.C Sağlık Bakanlığı Korona Tablosu [Web Document]. URL https://covid19. saglik.gov.tr/ [accessed on 22 April 2020]
  2. Villani A, Scalvenzi M, Fabbrocini G: Teledermatology: a useful tool to fight COVID-19. J Dermatolog Treat 2020;13:1
  3. Lebwohl M, Rivera-Oyola R, Murrell DF: Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol 2020;82:1217-8
  4. Wollenberg A, Flohr C, Simon D, et al: European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. J Eur Acad Dermatol Venereol 2020
  5. Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS: Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol 2020
  6. Li X, Geng M, Peng Y, Meng L, Lu S: Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020;10:102-8
  7. Shi Y, Wang Y, Shao C, et al: COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;27:1451-4
  8. Bikdeli B, Madhavan MV, Jimenez D, et al: COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol 2020
  9. Zhang J, Dong X, Cao Y, et al: Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020
  10. Jordan RE, Adab P, Cheng KK: Covid-19: risk factors for severe disease and death. BMJ 2020;368:m1198
  11. Price KN, Frew JW, Hsiao JL, Shi VY: COVID-19 and Immunomodulator/ Immunosuppressant Use in Dermatology. J Am Acad Dermatol 2020;82:e173-e5
  12. Zhao ZT, Ji CM, Yu WJ, et al: Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016;137:1742-50.e4
  13. Eichenfield LF, Bieber T, Beck LA, et al: Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. Am J Clin Dermatol 2019;20:443-56
  14. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C: Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020;79:667-8
  15. D’Antiga L: Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transplant 2020. 16. de Lang A, Osterhaus ADM, Haagmans BL: Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology 2006;353:474-81. 17